Total Grey Scale (GS) and power Doppler (PD) ultrasound scores
| Total GS | ||||||
| Visit | Estimated % GS >0 | Estimated median (95% CI) | Difference (95% CI) | T value, p value | ||
| ETN+MTX (n=60) | MTX-TT (n=60) | ETN+MTX (n=60) | MTX-TT (n=60) | |||
| Baseline | 75 | 70 | 3.00 (1.96 to 4.04) | 2.00 (0.70 to 3.30) | ||
| Week 12 | 56 | 69 | 1.00 (0.48 to 1.52) | 2.00 (1.22 to 2.78) | 1.00 (0.14 to 1.86) | t=2.29, p=0.024 |
| Week 24 | 60 | 58 | 1.00 (0.22 to 1.78) | 1.18 (0.02 to 2.34) | 0.18 (−1.21 to 1.57) | t=0.26, p=0.797 |
| Week 48 | 53 | 53 | 0.96 (0.32 to 1.60) | 0.94 (0.21 to 1.67) | −0.02 (−0.98 to 0.94) | t=−0.04, p=0.967 |
| Total PD | ||||||
| Visit | Estimated % PD >0 | Estimated 90th percentile* (95% CI) | Difference (95% CI) | T value, P value | ||
| ETN+MTX (n=60) | MTX-TT (n=60) | ETN+MTX (n=60) | MTX-TT (n=60) | |||
| Baseline | 47 | 45 | 5.00 (1.93 to 8.07) | 4.00 (0.93 to 7.07) | ||
| Week 12 | 15 | 15 | 1.00 (−0.80 to 2.80) | 3.00 (−0.07 to 6.07) | 1.82 (−1.79 to 5.43) | t=1.00, p=0.320 |
| Week 24 | 13 | 18 | 1.02 (−1.19 to 3.23) | 1.68 (−0.66 to 4.02) | 0.42 (−2.77 to 3.61) | t=0.26, p=0.795 |
| Week 48 | 8 | 13 | 0.06 (−2.62 to 2.74) | 0.70 (−1.13 to 2.53) | 0.46 (−2.28 to 3.20) | t=0.33, p=0.739 |
*Median was 0 in both groups at all visits. Unplanned use of 90th percentile instead of median as point of comparison.
ETN, etanercept; MTX, methotrexate; TT, treat-to-target.